Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

Sponsor
National University of Singapore
Study ID
NCT07444073
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Aging
  • Obesity & Overweight

Eligibility Criteria

Sex
ALL
Age
40 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • Not applicable. This is an observational study. — OTHER
    Not applicable. This is an observational study.

Study Details

This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.

Key Dates

First listed
Mar 2, 2026
Start date
Jun 1, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
440 participants (estimated)

Arms

  • Arm: NOVI Health weight management cohort
    Adults newly enrolled in the NOVI Health weight management program receiving standard-of-care GLP-1 receptor agonist therapy (semaglutide or tirzepatide) and lifestyle coaching (diet and physical activity) as part of routine clinical care. Medication type is determined by routine clinical care and patient-clinician decision-making, not by the research study.

Primary Outcome Measure

LinAge2 Biological Age [ Time Frame: Baseline and 6 months ]

Central Contacts

Related Studies